Atrial Fibrillation Management in Patients with COPD

Introduction to Rate Control

• The American College of Cardiology, American Heart Association, and European Society of Cardiology guidelines recommend calcium channel blockers like diltiazem over beta-blockers for rate control in atrial fibrillation in patients with COPD, due to the potential for significant conduction disturbances with combined treatment of diltiazem and beta-blockers 1, 2
• Calcium channel blockers may be preferred for long-term use over beta blockers in patients with bronchospasm or chronic obstructive pulmonary disease, according to the ACC/AHA/ESC guidelines 2

Diltiazem Monotherapy for Rate Control

• Diltiazem has been shown to effectively control heart rate both at rest and during exercise, and is associated with improved quality of life and exercise tolerance in AF patients 1, 2
• Diltiazem is specifically recommended for patients with COPD, with a typical maintenance dose of 120-360 mg daily in divided doses; slow-release formulations are available 2, 3
• The European Society of Cardiology recommends starting with lower doses and titrating carefully, given the patient's age and recent hospitalization 3

Monitoring and Alternative Therapies

• Regular assessment of heart rate and blood pressure, ECG monitoring for conduction abnormalities, and monitoring for signs of heart failure are necessary when using diltiazem for rate control 1, 2
• Digoxin can be considered for rate control at rest, though less effective during exercise, and may be appropriate for more sedentary elderly patients 1
• Amiodarone can be useful when other measures are unsuccessful, with a Class IIb recommendation for rate control when other agents are ineffective, but requires consideration of long-term toxicity risks if used chronically 1, 4